Patents by Inventor Nabil Lounis

Nabil Lounis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240043878
    Abstract: The present invention concerns a cell line comprising an endogenous dihydroorotate dehydrogenase (DHODH) and glutamine synthetase (GS) genes which are partially or fully inactivated, and its use for producing recombinant proteins.
    Type: Application
    Filed: September 21, 2021
    Publication date: February 8, 2024
    Applicant: SANOFI
    Inventors: Bruno Louis DUMAS, Mohammed Nabil LOUNIS
  • Publication number: 20230025088
    Abstract: The present invention is within the field of industrial protein production. The invention provides a novel expression system using dehydroorotate dehydrogenase (DHODH) as a selection marker in combination with leflunomide or a metabolite thereof, notably for use in mammalian cell lines. Expression vectors encoding DHODH, cell lines comprising said vectors and methods of producing recombinant proteins are also provided.
    Type: Application
    Filed: July 8, 2022
    Publication date: January 26, 2023
    Inventors: Bruno DUMAS, Nabil LOUNIS
  • Patent number: 11384342
    Abstract: The present invention is within the field of industrial protein production. The invention provides a novel expression system using dehydroorotate dehydrogenase (DHODH) as a selection marker in combination with leflunomide or a metabolite thereof, notably for use in mammalian cell lines. Expression vectors encoding DHODH, cell lines comprising said vectors and methods of producing recombinant proteins are also provided.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: July 12, 2022
    Assignee: Sanofi
    Inventors: Bruno Dumas, Nabil Lounis
  • Publication number: 20220177909
    Abstract: The present invention concerns a cell line comprising an endogenous dehydroorotate dehydrogenase (DHODH) gene which is partially or fully inactivated, and its use for producing recombinant proteins.
    Type: Application
    Filed: March 19, 2020
    Publication date: June 9, 2022
    Applicant: Sanofi
    Inventors: Bruno Louis DUMAS, Mohammed Nabil LOUNIS
  • Publication number: 20200199543
    Abstract: The present invention is within the field of industrial protein production. The invention provides a novel expression system using dehydroorotate dehydrogenase (DHODH) as a selection marker in combination with leflunomide or a metabolite thereof, notably for use in mammalian cell lines. Expression vectors encoding DHODH, cell lines comprising said vectors and methods of producing recombinant proteins are also provided.
    Type: Application
    Filed: December 26, 2019
    Publication date: June 25, 2020
    Inventors: Bruno DUMAS, Nabil LOUNIS
  • Patent number: 10557125
    Abstract: The present invention is within the field of industrial protein production. The invention provides a novel expression system using dihydroorotate dehydrogenase (DHODH) as a selection marker in combination with leflunomide or a metabolite thereof, notably for use in mammalian cell lines. Expression vectors encoding DHODH, cell lines comprising said vectors and methods of producing recombinant proteins are also provided.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: February 11, 2020
    Assignee: SANOFI
    Inventors: Bruno Dumas, Nabil Lounis
  • Publication number: 20170335292
    Abstract: The present invention is within the field of industrial protein production. The invention provides a novel expression system using dihydroorotate dehydrogenase (DHODH) as a selection marker in combination with leflunomide or a metabolite thereof, notably for use in mammalian cell lines. Expression vectors encoding DHODH, cell lines comprising said vectors and methods of producing recombinant proteins are also provided.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 23, 2017
    Inventors: Bruno DUMAS, Nabil LOUNIS
  • Patent number: 9334489
    Abstract: The present invention is within the field of industrial protein production. The inventors have designed and constructed a new expression system comprising an expression vector coding for a glutamine synthetase of human or dog origin, and a CHO cell line. More specifically, the invention pertains to a combination of (i) a DNA vector suitable for production of a recombinant protein, wherein said vector comprises a sequence coding for a glutamine synthetase, and (ii) a Chinese Hamster Ovary (CHO) cell line, wherein said GS comprises a sequence at least 94.5% identical to the sequence of SEQ ID NO: 1 or to the sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: May 10, 2016
    Assignee: SANOFI
    Inventors: Catherine Devaud, Bruno Dumas, Nabil Lounis
  • Publication number: 20150140607
    Abstract: The present invention is within the field of industrial protein production. The inventors have designed and constructed a new expression system comprising an expression vector coding for a glutamine synthetase of human or dog origin, and a CHO cell line. More specifically, the invention pertains to a combination of (i) a DNA vector suitable for production of a recombinant protein, wherein said vector comprises a sequence coding for a glutamine synthetase, and (ii) a Chinese Hamster Ovary (CHO) cell line, wherein said GS comprises a sequence at least 94.5% identical to the sequence of SEQ ID NO: 1 or to the sequence of SEQ ID NO: 2.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Applicant: SANOFI
    Inventors: Catherine Devaud, Bruno Dumas, Nabil Lounis